Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC34A2 | O95436 | 5/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | ACKR3 | P25106 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.41 |
| ▸ | RELA | Q04206 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | SLC34A1 | Q06495 | 1/20 | 0.40 |
| ▸ | SLC34A3 | Q8N130 | 1/20 | 0.40 |
| ▸ | SLC20A1 | Q8WUM9 | 1/20 | 0.40 |
| ▸ | CCR3 | P51677 | 1/20 | 0.40 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL265157 | 1.00 | SLC34A2 (0.56) | SLC34A2PKMACKR3SMN1; SMN2NPC1 | |
| SCHEMBL266832 | 0.93 | SLC34A2 (0.57) | SLC34A2ACKR3NPC1RAB9AENPP2 | |
| SCHEMBL266833 | 0.93 | SLC34A2 (0.57) | SLC34A2ACKR3NPC1RAB9AENPP2 | |
| SCHEMBL265864 | 0.93 | SLC34A2 (0.49) | SLC34A2PKMACKR3SMN1; SMN2NPC1 | |
| SCHEMBL265863 | 0.93 | SLC34A2 (0.49) | SLC34A2PKMACKR3SMN1; SMN2NPC1 | |
| SCHEMBL270414 | 0.91 | SLC34A2 (0.58) | SLC34A2ACKR3ENPP2 | |
| SCHEMBL270415 | 0.91 | SLC34A2 (0.58) | SLC34A2ACKR3ENPP2 | |
| SCHEMBL274311 | 0.91 | SLC34A2 (0.49) | SLC34A2PKMACKR3SMN1; SMN2NPC1 | |
| SCHEMBL267306 | 0.91 | SLC34A2 (0.49) | SLC34A2PKMACKR3SMN1; SMN2NPC1 | |
| SCHEMBL267681 | 0.90 | SLC34A2 (0.57) | SLC34A2ACKR3NPC1RAB9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120115851-A1 | COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2012-05-10 | — | — | US | disclosed |
| US-8134015-B2 | Compound inhibiting in vivo phosphorous transport and medicine containing the same | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2012-03-13 | — | — | US | disclosed |
| US-20060217426-A1 | Compound inhibiting in vivo phosphorous transport and medicine containing the same | KIRIN BEER KABUSHIKI KAISHA (JP) | 2006-09-28 | — | — | US | disclosed |
| EP-1614676-A1 | COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME | KIRIN BEER KABUSHIKI KAISHA (JP) | 2006-01-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060217426-A1 | Compound inhibiting in vivo phosphorous transport and medicine containing the same | SLC10A6, SLC7A1, SLC10A1 | SLC34A2 6/4885PKM 1697/4885ACKR3 751/4885 |
| US-20120115851-A1 | COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME | SLC34A1, SLC34A2, SLC20A2 | SLC34A2 2/4885PKM 1916/4885ACKR3 809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.